
08/20/2025
Prescription drug affordability remains one of the most pressing challenges in healthcare. Too often, the public debate focuses solely on pharmaceutical manufacturers, while overlooking the powerful role of middlemen in the system.
In his recent article, “Don’t Let Middlemen Off the Hook in the Drug Pricing Debate,” FSR Board Member Dr. Robert Levin examines how pharmacy benefit managers (PBMs) negotiate rebates and determine formularies in ways that often drive up out-of-pocket costs for patients instead of lowering them.
Dr. Levin calls for meaningful reforms that hold all players accountable and ensure that cost savings actually reach the patients who need them most.
Read his full article here: https://dcjournal.com/dont-let-middlemen-off-the-hook-in-the-drug-pricing-debate/
Published by InsideSources
President Trump’s recent directive to 17 pharmaceutical manufacturers demanding that U.S. drug prices align with the lowest prices in other developed